Novo-Nordisk is a pharmaceutical company based in Denmark. Its key divisions include Diabetes Care, Obesity Care, and Rare Diseases. Key products include Ozempic, Victoza, and insulin for diabetes; Wegovy and Saxenda for obesity; and treatments for rare blood and endocrine disorders.
Two potential return-on-investment results are: (a) +1.6% absolute return-on-investment (equivalent to +52.0% annualized return-on-investment for the next 11 days) if the stock is assigned early (on the last trading day prior to the March 22nd, 2022 ex-dividend date); OR (b) +2.3% absolute return-on-investment (equivalent to +49.5% annualized return-on-investment over the next 17 days) if the stock is assigned on the March 28th, 2024 options expiration date.
The simultaneous buy/write transaction was as follows:
3/11/2024 Bought 200 shares of Novo-Nordisk stock @ $132.34 per share.
3/11/2024 Sold 2 NVO March 28th, 2024 $128.00 Call options @ $6.32 per share.
3/22/2024 Upcoming ex-dividend of $.9299 per share
Two possible overall performance results (including commissions) would be as follows:
Covered Calls Net Investment: $25,205.34
= ($132.34 - $6.32) * 200 shares + $1.34 commission Net Profit Components:
(a) Options Income: +$1,262.66
= ($6.32 * 200 shares) - $1.34 commission
(b) Dividend Income (If Novo-Nordisk shares assigned on 3/21/2024, the business day prior to the 3/22/2024 ex-dividend date): = +$0.00; or
(b) Dividend Income (If NVO shares assigned at the 3/28/2024 options expiration date): +$185.98
= $.9299 per share x 200 shares
(c) Capital Appreciation (If Novo-Nordisk shares assigned early on 3/22/2024): -$868.00
= ($128.00 strike price -$132.34 stock purchase price) * 200 shares; or
(c) Capital Appreciation (If NVO shares assigned with stock above the $128.00 strike price at the March 28th options expiration): -$868.00
= ($128.00 -$132.34) * 200 shares
1. Potential Net Profit (If Novo-Nordisk shares assigned on 3/21/2024, the day prior to the March 22nd ex-dividend date): +$394.66
= (+$1,262.66 options income +$0.00 dividend income - $868.00 capital appreciation)
2. Potential Net Profit (If NVO price is above $128.00 strike price at the March 28th options expiration): +$580.64
= (+$1,262.66 options income +$185.98 dividend income - $868.00 capital appreciation)
1. Absolute Return-on-Investment (If Novo-Nordisk shares assigned early on 3/21/2024, the day prior to the March 22nd, 2024 ex-dividend date): +1.6%
= +$394.66/$25,205.34
Equivalent Annualized Return-on-Investment (If assigned early on day prior to ex-div date): +52.0%
= (+$394.66/$25,205.34) * (365/11 days)
2. Absolute Return-on-Investment (If Novo-Nordisk price is above $128.00 strike price at the March 28th options expiration date): +2.3%
= +$580.64/$25,205.34
Equivalent Annualized Return-on-Investment (If assigned on 3/28/2024 options expiration date): +49.5%
= (+$580.64/$25,205.34) * (365/17 days)
At least eight of the nine metrics used in the Covered Calls Advisor's Dividend Capture Strategy spreadsheet (see below) must be 'YES' prior to establishing a new Covered Calls position using the Covered Calls Advisor's Dividend Capture strategy. As shown below, eight of the nine criteria are achieved for this Novo-Nordisk Global Covered Calls position.